GB202016800D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- GB202016800D0 GB202016800D0 GBGB2016800.1A GB202016800A GB202016800D0 GB 202016800 D0 GB202016800 D0 GB 202016800D0 GB 202016800 A GB202016800 A GB 202016800A GB 202016800 D0 GB202016800 D0 GB 202016800D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- novel compounds
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2016800.1A GB202016800D0 (en) | 2020-10-22 | 2020-10-22 | Novel compounds |
| PCT/EP2021/079278 WO2022084479A1 (en) | 2020-10-22 | 2021-10-21 | N-cyanopyrrolidines with activity as usp30 inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2016800.1A GB202016800D0 (en) | 2020-10-22 | 2020-10-22 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202016800D0 true GB202016800D0 (en) | 2020-12-09 |
Family
ID=73727148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2016800.1A Ceased GB202016800D0 (en) | 2020-10-22 | 2020-10-22 | Novel compounds |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202016800D0 (en) |
| WO (1) | WO2022084479A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2001077073A1 (en) | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
| AU2007237874A1 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| CA2689989A1 (en) | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| CL2008002430A1 (en) | 2007-08-20 | 2009-10-16 | Glaxo Group Ltd | Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd. |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| TW201002318A (en) | 2008-04-18 | 2010-01-16 | Glaxo Group Ltd | Cathepsin C inhibitors |
| US20090264499A1 (en) | 2008-04-18 | 2009-10-22 | Jianghe Deng | Cathepsin C Inhibitors |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| WO2015017502A1 (en) | 2013-07-31 | 2015-02-05 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| EP3145505A4 (en) | 2014-05-19 | 2018-02-28 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof |
| JP2017516801A (en) | 2014-05-27 | 2017-06-22 | ファーマケア，インク． | Deubiquitinase inhibitor composition and method of delivery |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| PT3277677T (en) | 2015-03-30 | 2021-04-20 | Mission Therapeutics Ltd | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| CN109790112B (en) | 2016-09-27 | 2022-08-26 | 特殊治疗有限公司 | Cyanopyrrolidine derivatives having activity as USP30 inhibitors |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (en) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | Novel compounds |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| JP2020536863A (en) | 2017-10-06 | 2020-12-17 | フォーマ セラピューティクス，インコーポレイテッド | Ubiquitin-specific inhibition of peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| EP3793997B1 (en) | 2018-05-17 | 2024-03-13 | Forma Therapeutics, Inc. | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| WO2020036940A1 (en) | 2018-08-14 | 2020-02-20 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| EP4218934A1 (en) | 2018-10-05 | 2023-08-02 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| KR20230006487A (en) | 2020-04-08 | 2023-01-10 | 미션 테라퓨틱스 엘티디 | N-cyanopyrrolidine with activity as a USP30 inhibitor |
-
2020
- 2020-10-22 GB GBGB2016800.1A patent/GB202016800D0/en not_active Ceased
-
2021
- 2021-10-21 WO PCT/EP2021/079278 patent/WO2022084479A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022084479A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202008749D0 (en) | Novel compounds | |
| GB2605894B (en) | Novel compounds | |
| GB202016800D0 (en) | Novel compounds | |
| GB202118096D0 (en) | Novel compounds | |
| GB202117608D0 (en) | Novel compounds | |
| GB202117366D0 (en) | Novel compounds | |
| GB202115150D0 (en) | Novel compounds | |
| GB202115156D0 (en) | Novel compounds | |
| GB202115158D0 (en) | Novel compounds | |
| GB202113016D0 (en) | Novel compounds | |
| GB202110809D0 (en) | Novel compounds | |
| GB202109446D0 (en) | Novel compounds | |
| GB202108873D0 (en) | Novel compounds | |
| GB202106872D0 (en) | Novel compounds | |
| GB202106871D0 (en) | Novel compounds | |
| GB202101935D0 (en) | Novel compounds | |
| GB202101734D0 (en) | Novel Compounds | |
| GB202101573D0 (en) | Novel compounds | |
| GB202101280D0 (en) | Novel compounds | |
| GB202019590D0 (en) | Novel Compounds | |
| GB202019588D0 (en) | Novel Compounds | |
| GB202016758D0 (en) | Novel compounds | |
| GB202016785D0 (en) | Novel compounds | |
| GB202016791D0 (en) | Novel compounds | |
| GB202016689D0 (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |